To determine the course of depression and the effects of treatment during pregnancy and into the postpartum period.
Clinical Implications
• Overall, depression symptoms decrease over the course of pregnancy into the postpartum period.
• Treatment significantly reduces depressive symptoms in pregnant and postpartum women.
• Women engage more in counselling during pregnancy, while medication is more acceptable in the postpartum period.
Limitations
• The participants were more likely to be married, better educated, and have higher incomes, compared with women in the general population.
• Women with depression may have been more likely to volunteer to participate in a study about feelings in pregnancy.
• A diagnostic assessment for clinical depression was not done. F or most women, pregnancy and childbirth are happy times, [1] [2] [3] but depression is at least as common during pregnancy and in the postpartum period as in nonpregnant women. 1, 2 A recent study 2 estimated new onsets of depression at 1.6% during pregnancy and 5.7% in the postpartum period, and recurrences at 3.7% during pregnancy and 7.7% during the postpartum period. The literature suggests that the usual pattern for depressive symptoms is an increase in the first trimester, improvement over the course of pregnancy, and a rise again just before or after delivery. 2, 3 After delivery, the highest prevalence occurs in the first 3-months and gradually falls over the next year. 2 Because there is no gold standard measure, the estimated prevalence of depression can vary widely. Studies using self-report instruments such as the EPDS can find higher prevalence than those based on diagnostic interviews. 1 The most common diagnostic category assessed by standard interviews is that of MDD, 4 but minor depression that involves fewer symptoms and less impairment than MDD, 4 is sometimes included in the broad category of depression. 1 Sociodemographic factors and the availability of treatment can also affect the prevalence. 1 Despite these caveats, it is an established finding that depression is common in pregnancy and in the postpartum period and that this is a pressing public health issue. 5 Maternal depression is associated with relationship problems, engagement in risky behaviours, and adverse effects on maternal and infant health. [6] [7] [8] [9] [10] [11] Emotional withdrawal and disengagement from normal functions may lead to a breakdown of primary relationships and threaten social supports. 12 The partners of women with postpartum depression are more likely to manifest depressive symptoms, especially if the woman is severely depressed. 13 Antenatal depression is associated with an increased risk of spontaneous abortion and pre-eclampsia, 14 as well as higher rates of surgical deliveries that may put the fetus at risk. Infants born to mothers with depression are more likely to experience an increased risk for preterm delivery, lower Apgar scores, lower birth weight, less frequent and shorter duration of breastfeeding, 15 and twice the rate of admission to neonatal intensive care. 16 These babies are fussier 17 and are more likely to fail to thrive. 18 Additionally, a postpartum mother who is depressed may not be able to provide the loving and consistent care that her child needs, which may interfere with mother-baby attachment. 18, 19 Compared with infants with no attachment problems, insecurely attached infants are at a greater risk for developmental psychological challenges as they mature. 8 Pregnant and breastfeeding women are often reluctant to take ADs 5 because, despite evidence of their relative safety, compared with untreated depression, there are ongoing concerns about their effects on the developing infant. [20] [21] [22] A few studies have observed little benefit to pregnant women who take ADs, compared with those who do not, 5, 23 which is consistent with evidence that ADs have a small benefit for symptom relief, compared with placebos, for mild to moderate depression. 24, 25 Other studies have shown benefits from psychological therapies delivered by nurses, family physicians, or mental health specialists, 5 compared with routine care, but controlled trials have difficulty showing a specific treatment effect for psychotherapy, compared with general education and coping instructions. 26 Studies have also shown that low rates of participation in therapy and follow-up with treatment are a concern. 5,26
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To reflect current practice, as well as for ethical reasons, we offered to refer women who screened positive for probable depression on the EPDS for further assessment. We worked with physicians and mental health services to ensure that women in our study would have access to accelerated Conclusions : Nous confirmons que les symptômes dépressifs s'améliorent au cours de la grossesse et du postpartum, particulièrement chez les femmes qui reçoivent un traitement. Notre étude est unique en ce qu'elle tient compte des antécédents de dépression, de l'état des traitements précédents et actuels, et de la nature longitudinale des données. assessment and treatment, which led to the development of a maternal mental health service. 27 Consequently, we wanted to understand the effect of our practice of referring women for assessment and their potential uptake of treatment on the prevalence of depression.
The goal of our study was to increase our understanding of the changing pattern of depression, when treatment is taken into account, from early pregnancy to late pregnancy, and into the postpartum period. We hypothesized, as the literature suggests that women would become less depressed over the course of pregnancy into postpartum, 28 that depression would increase in the postpartum period and that those women who received treatment would have less depression symptoms than those who did not have treatment. The University of Saskatchewan Behavioural Research Ethics Board approved the study. Signed informed consent was obtained from all participants.
Method
Participants were recruited from the community through posters in doctors' offices, maternity stores, daycares, recreation facilities, and hospitals, as well as newspaper and radio ads, and word of mouth. Pregnant women who were at less than 20 weeks gestation, English speaking, and residing within 1 of 2 health regions were enrolled in The Feelings in Pregnancy and Motherhood Study; all others were excluded. We collected self-report data through face-to-face interviews by trained research assistants at 3 times: Time 1, early pregnancy (17.4 ± 4.9 weeks); Time 2, late pregnancy (30.6 ± 2.7 weeks); and Time 3, postpartum (4.2 ± 2.1 weeks).
Depression was assessed using the EPDS and defined as a score of 12 or more. The EPDS is the most widely used perinatal depression screen, worldwide, and it has been validated against interview schedules and other self-report instruments. 3 Sensitivity of the EPDS ranges from 73% to 100% and specificity from 68% to 96% in antenatal and postpartum women. [29] [30] [31] The EPDS and other data were completed by the participant, with the interviewer available to assist if necessary. Psychosocial data (for example, worry, stressors, social support, and abuse), behavioural information (for example, alcohol, drug, tobacco use, and exercise), and treatment status (for example, currently taking psychotropic medications and [or] involved in counselling) were collected at each time (1, 2, and 3). Women were also asked if they had received any counselling or taken any specific medications since the previous interview. Data were also collected on various sociodemographic factors (for example, income, education, marital status, employment status, and ethnicity) as well as history of depression, mood problems, and history of treatment and treatment status at the initial interview.
Because we identified all women who had screened positive for probable depression (EPDS ≥ 12) and urged them to seek further assessment for possible treatment, we expected that some women would be in treatment at various points during their pregnancy. Therefore, at the initial analysis, we further categorized women into 3 groups according to their treatment and depression status. The first group of women were neither treated nor depressed (that is, EPDS < 12). The second group of women reported being treated, regardless of the EPDS score. The third group were women who had an EPDS of 12 or more (that is, depressed) but did not report treatment.
Analysis
Descriptive analysis was completed on all variables. The difference between the completers and noncompleters was tested using chi-square analysis. To determine the predictors of depression at each time, variables were compared between women with depression (EPDS ≥ 12) and without depression using t tests and chi-square analysis. Significant variables (P < 0.10) were entered into the model (for example, age or ethnicity). Finally, the history of depression, history of depression treatment, and specific treatment variables (that is, counselling or medication), as well as the depression status at the previous time in the study, were entered into the model.
To account for the longitudinal nature of our data we used a generalized linear model, using the GEE analysis. 32, 33 The GEE analysis allows us to predict the mean EPDS score changes among groups, taking into account the clustering of measures within women (intraclass correlation). We fitted the model by quasi-likelihood method, using independent correlation structure and identity link function within study subjects (n = 649). Consequently, the n remains at 649 in all figures where the GEE analysis was used, despite the overall change in the numbers of women over time. The Wald chisquare test was used to test the significance of the hypotheses. We compared different groups of women:
1. depressed and nondepressed; 2. neither depressed nor treated (the reference category), treated whether depressed or not depressed, and depressed and not treated;
3. counselled and noncounselled; and 4. use of psychotropic medication, compared with no psychotropic medication.
In all models, we controlled for age, ethnicity, history of depression, and history of depression treatment over time. We also examined the effect modification for the key independent variables for mean EPDS change over time by evaluating the interaction terms in the model. All analyses were done using SPSS, Version 18 (SSPS Inc, Chicago, IL). Statistical significance was set at P < 0.05.
Results

Participants
There were 649 women at the onset of our study (17.4 ± 4.9 weeks pregnant), 603 at Time 2 (30.6 ± 2.7 weeks pregnant), and 593 at Time 3 (4.2 ± 2.1 weeks postpartum).
Thirty-five women were lost to follow-up; and 21 women did not complete the study because of fetal and neonatal loss. Table 1 describes the participants at Time 1, the onset of the study. At Time 3, the women who did not complete the study, compared with those who did, were significantly more likely to be younger, Aboriginal, had less than Grade 12 education, less than $40 000 income, unplanned pregnancies, and were depressed.
Prevalence
The unadjusted prevalence of depression (EPDS ≥ 12) was 14.1% (n = 91) at Time 1, 10.4% (n = 62) at Time 2, and 8.1 % (n = 48) at Time 3. Twenty-one per cent of women (n = 16) who were depressed in early pregnancy were also depressed in the postpartum period and 27% (n = 13) of women who were depressed in late pregnancy experienced depression in postpartum.
Depression Over Time
Women who were not depressed (EPDS < 12) at Time 1, early pregnancy, continued to experience improving mood (that is, decreasing mean EPDS scores) from pregnancy to the postpartum period, while the mean score of women who were depressed at Time 1 continued to increase over the perinatal period, indicating a worsening of mood over that time. Specifically, after controlling for age, ethnicity, and history of depression, and previous depression treatment, the mean EPDS score is significantly higher from the nondepressed to depressed group in each time period (parameter estimate β = 10.312; SE = 0.4990; 95% CI 9.334 to 11.290; P < 0.001) (group effect), the mean EPDS score is significantly different from antenatal to postpartum period in both the depressed and nondepressed groups for Time 1 and Time 3 (parameter estimate β = 0.848; SE = 0.1467; 95% CI 0.561 to 1.136; P = 0.001), while for Time 2 and Time 3 the parameter estimates show the time effect (β = 0.481; SE = 0.1373; 95% CI 0.212 to 0.750; P < 0.001). Finally, we see that the mean EPDS score is significantly different from the depressed Time 1, compared with women who were not depressed at Time 3, (parameter estimate β = −1.882; SE = 0.6118; 95% CI = −3.081 to −0.683; P < 0.001), but not significantly different from women who were depressed at Time 2 (parameter estimate β = −0.986; SE = 0.6508; 95% CI = −2.262 to 0.289; P = 0.12) after controlling for age, ethnicity, history of depression, and history of depression treatment.
Treatment Status
Forty-six per cent (n = 298) of women had a self-reported history of depression and 26% (n = 168) had a history of depression treatment (counselling and [or] psychotropic medication). Twelve per cent of women were already receiving treatment (n = 78) when they entered the study. This percentage of women in treatment does not differ at any given time (~12%) throughout the study; however, over the course of the study, the total number of women who received treatment approached 22% (n = 125). Sixty women (9.2%) who were depressed were not in treatment at the onset of the study; by completion of the study this was reduced to 32 women (5.4%).
There were some differences between the 3 groups of women:
1. neither depressed nor treated; 2. treated whether depressed or not depressed; and 3. depressed and not treated.
Compared with women who were neither depressed nor treated, untreated women with depression were significantly more likely to be aged 24 years or younger, more stressed, have less support, have a history of depression and mood problems, and to use alcohol (P < 0.001). The treated women shared the same sociodemographic characteristics, but were more likely to smoke rather than to drink alcohol, compared with women who were either depressed and untreated or depressed and not treated.
Patterns of Depression
The predicted mean depression score of women treated decreased most significantly (parameter estimate β = 0.603; SE = 0.1648; 95% CI 0.280 to 0.926; P < 0.001) over the course of pregnancy to postpartum, compared with women who were not treated. The association between treatment and decreased depression remained significant when controlling for the sociodemographic variables, which were significant in the bivariate analysis (age and ethnicity) as well as the history of depression and previous depression treatment. Knowing that treatment overall had a significant effect on depression status for some women, we sought to determine the effects of specific treatment modalities (that is, counselling or psychotropic medication on depression status).
Treatment Over Time
Women used significantly less psychotropic medication in pregnancy, 4.3% (n = 27) at Time 1 and 5.4% (n = 33) at Time 2, compared with 7.8% (n = 46) of the women who were taking medication in the postpartum period. Concurrently, the number of women in counselling decreased over pregnancy into the postpartum period (9.4% [n = 61], 8.5% [n = 51], and 7.8% [n = 46], respectively). Participation in counselling decreased depression scores significantly from Time 1 to Time 2 (parameter estimate β = 0.967; SE = 0.1977; 95% CI 0.580 to 1.355; P < 0.001) and from Time 1 to Time 3 (parameter estimate β = 0.427; SE = 0.1848; 95% CI 0.064 to 0.789; P = 0.02) in both groups (adjusting for age, ethnicity, history of depression, history of depression treatment, and present psychotropic medication use). Depression scores were higher in those women using psychiatric medications; the depression scores dropped between Time 1 to Time 2 whether or not the woman was taking psychiatric medications (parameter estimate β = 1.107; SE = 0.1927; 95% CI 0.729 to 1.484; P < 0.001). Depression scores also decreased from Time 1 to Time 3 (parameter estimate β = 0.548; SE = 0.1810; 95% CI 0.194 to 0.903; P = 0.002); these effects remained significant in both groups when controlling for sociodemographic status, history of depression, history of depression treatment, and counselling.
Discussion
The prevalence of depression (14.1%) that we determined in the first trimester is in the range of reported prevalence rates for antenatal depression in the literature. A recent systematic review estimated a prevalence of 11%. 1 One would expect a higher prevalence in our study as we advertised it as a study of feelings in pregnancy and it is likely that women with an interest in depression were more likely to volunteer. Initially, we noted an increase in depression symptoms from pregnancy into the postpartum period, but after adjusting for treatment status, we confirm that mean depression scores and the percentage of women who are depressed decreases from early pregnancy into the postpartum period. 1, 2, 28, 34 Importantly, our data also indicate that both medication and counselling treatments are effective, as demonstrated by lower mean scores and lower predicted probabilities for depression symptoms as determined in the GEE analyses. This is consistent with the literature, including a meta-analysis of treatment effects. 35, 36 We report that 21% of women who were depressed in early pregnancy and 27% in late pregnancy continued to be depressed into the postpartum period, compared with another study in which 66% of women who were depressed in pregnancy went on to develop postpartum depression. Screening women for depression at the 2 interviews in pregnancy and referring them for treatment if they screened positive was not only an ethically important decision but also a unique feature of our study that more accurately (albeit likely showing lower depression rates over time) captures the experience of women who have depression symptoms in pregnancy. 35 We did note a significantly greater improvement for depressive symptoms of women who received treatment in pregnancy, both for counselling and medication use. Recent evidence, summarized in several meta-analyses and reviews, has indicated that ADs produce some response over the short term, 24 but has questioned the efficacy of ADs for sustaining remission over the longer term 25 ; duration of benefit is not as an important an issue in pregnancy, but may be in the postpartum period. Reports have also questioned the efficacy of AD treatment for depression in pregnancy, based on women with MDD reporting similar symptom levels whether or not they were taking ADs. 23 However, these were not randomized trials. The evidence for increased relapses (68%) among pregnant women who discontinue existing AD treatment is stronger. 37 Women who were depressed and untreated were significantly more likely to use alcohol than women who were neither depressed nor treated. These women may have already been using alcohol as self-medication, 38 but it may also be that women who use alcohol avoid contact with health care providers, especially while pregnant or with a new baby.
The rates of medication use during pregnancy (4.3% Time 1 and 5.5% Time 2) are comparable with Wisner et al's 39 estimates of 3%, with up to 13% of women taking an AD at some point during pregnancy in other studies. 40, 41 Antenatal AD use is an ongoing source of debate owing to concerns about potential adverse effects on the fetus, 39 which may explain the increase in the use of ADs during the postpartum period. 42 This concern does not mean that women with depression need to remain untreated and depressed, as there does seem to be a benefit to women who engage in counselling.
The evidence for psychological interventions, such as counselling during pregnancy, is robust (with an effect size of Hedges' g = 0.65), comparable with the effect size for adult depression in nonpregnant individuals. 35 The indication is that psychological treatments, which contain an interpersonal component and are delivered individually, may be more effective. 35, 36 A particular strength of our study was the high rate of follow-up from Time 1 to Time 3, with only 9% (n = 56) overall attrition compared with other studies. 2 Another novel component of our study is that we made a systematic attempt to identify or establish specialized treatment services for women who were depressed and documented whether they obtained help. 27 However, as with all studies, there are some limitations. The women in our study were more likely to be married, well educated, and have higher incomes, compared with women in the general population; therefore, caution should be exercised in generalizing the results to all women. The study was titled Feelings in Pregnancy and Motherhood, which may have encouraged women with emotional or psychiatric problems to participate. We used a score of 12 or more as indicative of probable depression, but different thresholds have been used in some studies and different cut-off scores may be used at different stages of pregnancy. 3 The EPDS is a validated depression screening instrument suitable for the population in this study; however, no confirming interviews for the presence of a diagnosis of depression were done.
Conclusions
Our study confirms that depression symptoms decrease over the course of pregnancy into postpartum, and that this symptom improvement is greatest when a woman is engaged in treatment. This improvement in symptoms has both statistical and clinical significance even in women with a history of depression, a history of depression treatment, and present treatments. Women who resisted going for treatment were more likely to have a history of mood problems and use alcohol, which points to an increased need for systematic screening for alcohol use and other psychiatric problems in pregnancy.
Our study is unique; it reflects the pattern of depression as well as the effects of counselling and medication use over time in a well-retained sample of women from the general population.
